Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $53.1667.

A number of brokerages have recently issued reports on ELVN. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. HC Wainwright increased their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Mizuho increased their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, March 25th. Finally, The Goldman Sachs Group increased their target price on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, May 8th.

Insider Buying and Selling

In other news, Director Richard A. Heyman sold 1,230 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the transaction, the director owned 22,647 shares in the company, valued at $592,898.46. This trade represents a 5.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Benjamin Hohl sold 10,000 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the transaction, the chief financial officer owned 51,000 shares in the company, valued at $1,508,580. This trade represents a 16.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 25.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ELVN. KBC Group NV acquired a new position in Enliven Therapeutics in the 1st quarter valued at $38,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in Enliven Therapeutics in the 4th quarter valued at $83,000. Finally, Quantbot Technologies LP raised its stake in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Trading Up 3.0%

Enliven Therapeutics stock opened at $43.56 on Thursday. Enliven Therapeutics has a 12 month low of $14.78 and a 12 month high of $48.53. The stock’s 50 day simple moving average is $38.01 and its two-hundred day simple moving average is $27.91. The firm has a market cap of $2.65 billion, a PE ratio of -26.08 and a beta of 0.32.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. On average, equities research analysts forecast that Enliven Therapeutics will post -1.59 EPS for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.